Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL® at ASCO Breast Cancer Symposium
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St indexes climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Strategy stock jumps 7% as firm shifts to active capital management
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results
September 23, 2015 11:00 AM EDTBrean Capital reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX), and raised the price target to $55.00 (from $45.00), following announced positive top-line results from HTX-011. Analyst Jonathan Aschoff projects HTX-011 to have a higher price, and drive significant value.
Aschoff commented, "Yesterday, Heron announced positive top-line results from its Phase 2 trial of HTX-011 for the treatment of post-operative pain after bunionectomy. This randomized, placebo-controlled, double-blind, Phase 2 trial evaluated the... More
Heron Therapeutics (HRTX) to Present SUSTOL Data as CINV Prevention at ASCO 2015 Breast Cancer Symposium
September 22, 2015 8:06 AM EDTHeron Therapeutics (NASDAQ: HRTX) announced that data from Herons recently completed MAGIC Study of SUSTOL (granisetron) Injection, extended release, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC), will be presented at the American Society of Clinical... More
